ArticleObesity pillars2026
Treatment resistant obesity among midlife women receiving care from a specialized weight management clinic.
Article in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity is a complex chronic disease conveying significant health risk. Women with obesity have greater risk for certain obesity associated conditions and midlife is when women experience an increase in their overall obesity prevalence and severity. Some midlife women experience treatment resistant obesity (TRO), a phenomenon not previously explored. The purpose of this research was to determine the prevalence of TRO, or failure to achieve ≥5% total body weight loss after one year of medically specialized obesity treatment, among midlife women and to identify factors associated with the phenomenon. Methods: A retrospective cohort study was completed using information from the electronic health records of 203 midlife women with obesity who received one year of medically specialized obesity care from providers certified in obesity medicine. Quantitative analysis determined the prevalence of TRO among midlife women and found associations between TRO and certain biopsychosocial factors. Results: More than 27% of participants in this study demonstrated TRO. The use of FDA approved injectable medications and the dietary modification of lowering carbohydrates demonstrated associations with TRO. Participants were more likely to demonstrate TRO if they did not use FDA approved injectable medications (OR = 3.49, p = 0.0002) or follow a diet lower in carbohydrates (OR = 2.18, p = 0.035). Conclusions: More than a quarter of midlife women with obesity who receive medically specialized obesity care for one year may fail to achieve ≥5% total body weight loss and demonstrate TRO. The combination of lowering dietary carbohydrates and taking FDA approved injectable medications for weight loss in midlife women may reduce their risk of TRO. Incorporation of these two strategies alone does not eliminate the occurrence of TRO among midlife women and therefore additional research into this phenomenon is necessary to determine more efficacious treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.